Abstract
The expression of CCR5 and CXCR3, two chemokine receptors involved with homing of T cells to inflamed tissue, was examined longitudinally on CD4+ and CD8+ T cells in patients with a first demyelinating event of the central nervous system (CNS) randomized to receive i.m. injections of interferon-beta1a (IFN-beta1a) or placebo. Blood for analysis was collected before and 48 h after injection at baseline and after 3 and 12 months of treatment. The results showed that treatment with IFN-beta1a did not affect numbers of T cells expressing CCR5 and CXCR3 during the first 12 months of treatment, either at the peak of biological response or at the trough of interferon effect, at steady-state.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
CD4-CD8 Ratio / statistics & numerical data
-
Down-Regulation* / immunology
-
Drug Administration Schedule
-
Follow-Up Studies
-
Humans
-
Injections, Intramuscular
-
Interferon beta-1a
-
Interferon-beta / administration & dosage*
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / immunology
-
Receptors, CCR5 / biosynthesis*
-
Receptors, CCR5 / blood
-
Receptors, CXCR3
-
Receptors, Chemokine / biosynthesis*
-
Receptors, Chemokine / blood
-
T-Lymphocyte Subsets / immunology*
-
T-Lymphocyte Subsets / metabolism*
-
Time Factors
Substances
-
CXCR3 protein, human
-
Receptors, CCR5
-
Receptors, CXCR3
-
Receptors, Chemokine
-
Interferon-beta
-
Interferon beta-1a